Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease. [PDF]
Eur J Hosp Pharm, 2022 Martín-Gutiérrez N +5 more
europepmc +1 more source
Biosimilar CT-P13 comparable to infliximab in active RA [PDF]
Nature Reviews Rheumatology, 2013 openaire +1 more source
A critical review of the United States regulatory pathways for determining the equivalence of efficacy between CT-P13 and original infliximab (Remicade®). [PDF]
Drug Des Devel Ther, 2020 Kim S, Kim S, Lee H.
europepmc +1 more source
Post-Marketing Pooled Safety Analysis for CT-P13 Treatment of Patients with Immune-Mediated Inflammatory Diseases in Observational Cohort Studies. [PDF]
BioDrugs, 2020 Lee SJ +5 more
europepmc +1 more source
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update [PDF]
, 2014 Aletaha, D. (Daniel) +32 more
core +1 more source
Remsima® – the first biosimilar infliximab CT-P13
Gastroenterologie a hepatologie, 2017 openaire +1 more source
Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials. [PDF]
BioDrugs, 2020 Jørgensen KK +28 more
europepmc +1 more source
A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn’s Disease Treated with Adalimumab or Infliximab [PDF]
, 2016 Kaoru Yokoyama +3 more
core +1 more source
Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial [PDF]
, 2016 Alan Watkins +4 more
core +1 more source
Effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting in patients with Crohn's disease or ulcerative colitis. [PDF]
J Drug Assess, 2019 Gheorghe C, Svoboda P, Mateescu B.
europepmc +1 more source